½ÃÀ庸°í¼­
»óǰÄÚµå
1621575

¼¼°èÀÇ ¿ì·ÎŰ³ªÁ¦ ½ÃÀå : À¯Çü, Åõ¿© °­µµ, ÀûÀÀÁõ, ¿ëµµº° ¿¹Ãø(2025-2030³â)

Urokinase Market by Type (Urokinase Powder, Urokinase Solution), Dose Strength (250000 Unit, 5000 Unit), Indication, Application - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 194 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¿ì·ÎŰ³ªÁ¦ ½ÃÀåÀº 2023³â¿¡ 17¾ï 6,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 18¾ï 5,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 5.30%·Î ¼ºÀåÇϰí, 2030³â¿¡´Â 25¾ï 2,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¿ì·ÎŰ³ªÁ¦´Â Ç÷ÀüÀ» ¿ëÇØ½ÃŰ´Â µ¥ »ç¿ëµÇ´Â È¿¼ÒÀ̸ç, ƯÈ÷ ½É±Ù °æ»ö°ú Æó»öÀüÁõ°ú °°Àº Ç÷Àü ¿ëÇØ ¿ä¹ý¿¡¼­ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. Áß¿äÇÑ ±¸¸í Ä¡·á¸¦ Á¦°øÇÏ´Â ÀÀ±Þ ÀÇ·á¿¡ Àû¿ëÇÏ¿© Á¤ÀÇµÇ¾î ¼ö¿ä°¡ È®´ëµÇ°í ÀÖ½À´Ï´Ù. Á¶»ç ´ë»óÀº º´¿ø, Àü¹® Ŭ¸®´Ð, ¿¬±¸¼Ò ¹× Ä¡·áÀû, ½ÇÇèÀûÀ¸·Î »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ³ôÀº Ä¡·áºñ, ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç, Á¶Á÷ Çö󽺹̳ë°Õ Ȱ¼ºÈ­ ÀÎÀÚ(tPA)¿Í °°Àº ´ëü ¿ä¹ý°úÀÇ °æÀï µîÀÌ ¼ºÀåÀÇ Å« À庮ÀÌ µÇ°í ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 17¾ï 6,000¸¸ ´Þ·¯
ÃßÁ¤³â(2024) 18¾ï 5,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 25¾ï 2,000¸¸ ´Þ·¯
CAGR(%) 5.30%

ÇöÀçÀÇ °³¹ß ±âȸ´Â ½Å±Ô Ä¡·á ¿µ¿ª¿¡ ¿ì·ÎŰ³ªÁ¦ÀÇ Àû¿ë È®´ë, ÀǽÄÀÇ Çâ»ó°ú Çコ Äɾî ÀÎÇÁ¶óÀÇ °³¼±¿¡ ÀÇÇÑ °³¹ß µµ»ó Áö¿ª¿¡¼­ÀÇ »ç¿ë Áõ°¡, ºñ¿ë Àý°¨À» À§ÇÑ ¹ÙÀÌ¿À Á¦Á¶¿¡¼­ÀÇ °³¹ßÀÇ °¡´É¼º¿¡ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±âȸ¸¦ Ȱ¿ëÇϱâ À§ÇØ ±â¾÷Àº Àü·«Àû ÆÄÆ®³Ê½Ê°ú R&D ÅõÀÚ¿¡ ÁÖ·ÂÇÏ°í ±ÔÁ¦ ±âÁØÀ» ÁؼöÇϸ鼭 ¿ì·ÎŰ³ªÁ¦ÀÇ ¿ëµµ¸¦ ´Ù¾çÈ­½ÃÄÑ¾ß ÇÕ´Ï´Ù. ¸®½ºÅ©·Î´Â ºÎÀÛ¿ë °¡´É¼º, ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ ÃâÇö, ¿øÀç·áÀÇ ÀÌ¿ë °¡´É¼ºÀÇ º¯µ¿ µîÀÌ ÀÖ¾î ½ÃÀå ħÅõ¿¡ °úÁ¦°¡ µÇ°í ÀÖ½À´Ï´Ù.

Çõ½ÅÀÇ ÃÊÁ¡Àº Á¦ÇüÀÇ Æ¯À̼º°ú È¿´É Çâ»ó, Ç÷Àü ¿ëÇØ ¿ä¹ýÀ» °³º°È­Çϱâ À§ÇÑ ¸ÂÃãÇü ÀÇ·á, Àü´Þ ¸ÞÄ¿´ÏÁòÀÇ °³¼±ÀÔ´Ï´Ù. ¶ÇÇÑ, ´ë±Ô¸ð ÀÓ»ó½ÃÇè¿¡ ´ëÇÑ ÅõÀÚ´Â ¿ì·ÎŰ³ªÁ¦ÀÇ ±¤¹üÀ§ÇÑ ÀÀ¿ë¿¡ ´ëÇÑ ÅëÂû·ÂÀ» Á¦°øÇÏ¿© ±ÔÁ¦ ´ç±¹°ú ÁöºÒÀÚ¿¡°Ô À¯ÀÍÇÑ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ´Â ±ÍÁßÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù. °æÀï ±¸µµ¸¦ Ư¡À¸·ÎÇÏ´Â ¿ì·ÎŰ³ªÁ¦ ½ÃÀåÀº ¿ªµ¿ÀûÀ̸ç Áö¼ÓÀûÀÎ ±â¼ú Çõ½Å°ú ºñ¿ë È¿À²ÀûÀÎ »ý»ê ¹× ±¤¹üÀ§ÇÑ ÀÀ¿ëÀ»À§ÇÑ Àü·«Àû Ãß¼¼°¡ Áö¼ÓÀûÀÎ ¼ºÀå°ú ½ÃÀå °úÁ¦¿¡ ´ëÇÑ Åº·Â¼ºÀÇ ¿­¼è µË´Ï´Ù.

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ¿ì·ÎŰ³ªÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

¿ì·ÎŰ³ªÁ¦ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ðÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÅõÀÚ°áÁ¤, Àü·«Àû °áÁ¤ Á¤¹ÐÈ­, »õ·Î¿î ºñÁî´Ï½º ±âȸ ȹµæ¿¡ ´ëºñÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ À§ÇèÀ» ¿ÏÈ­ÇÒ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ»º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¼¼°è Æó»öÀüÁõ ¹× °ü»óµ¿¸Æ Ç÷ÀüÁõÀÇ À¯º´·ü Áõ°¡
    • ¿ì·ÎŰ³ªÁ¦¿¡ ±âÃÊÇÑ ÀǾàǰ¿¡ ´ëÇÑ Á¤ºÎÀÇ ÁöÁöÀûÀÎ ½ÂÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¾à¹° °³¹ß ºñ¿ëÀÇ »ó½Â°ú ´ëü ¾à¹°ÀÇ °¡¿ë¼º
  • ½ÃÀå ±âȸ
    • ¿ì·ÎŰ³ªÁ¦ÀÇ Àû¿ë¼ºÀ» Çâ»ó½Ã۱â À§ÇÑ Áö¼ÓÀûÀÎ ¿¬±¸ °³¹ß
    • ¿ì·ÎŰ³ªÁ¦ ±â¹ÝÀÇ Ä¡·á È¿°ú¸¦ ³ôÀ̱â À§ÇÑ Ã·´Ü ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ Ã¤¿ë
  • ½ÃÀåÀÇ °úÁ¦
    • ¿ì·ÎŰ³ªÁ¦°è ÀǾàǰ¿¡ ¼ö¹ÝµÇ´Â ºÎÀÛ¿ë

Porter's Five Force : ¿ì·ÎŰ³ªÁ¦ ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ¿ì·ÎŰ³ªÁ¦ ½ÃÀå °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¸¦ ÇÇÇÒ ¼ö ÀÖÀ¸¸ç ´õ °­ÀÎÇÑ ½ÃÀå¿¡¼­ Æ÷Áö¼Å´×À» º¸Àå ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ¿ì·ÎŰ³ªÁ¦ ½ÃÀå¿¡¼­ ¿ÜºÎ ¿µÇâÀ» ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ¿ì·ÎŰ³ªÁ¦ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÏ¸é ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ°¡µÇ¾î ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : ¿ì·ÎŰ³ªÁ¦ ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

¿ì·ÎŰ³ªÁ¦ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õ´Â °æÀïÀÌ Ä¡¿­ÇØÁö¸é¼­ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» Çϱâ À§ÇØ ÇÊ¿äÇÑ Áö°ß À» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ¿ì·ÎŰ³ªÁ¦ ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ¿ì·ÎŰ³ªÁ¦ ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ºÐÇÒÇϰí Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× ±ÇÀå : ¿ì·ÎŰ³ªÁ¦ ½ÃÀå¿¡¼­ ¼º°øÀ» À§ÇÑ ±æÀ» ±×¸®±â

¿ì·ÎŰ³ªÁ¦ ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺠°­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÎ ¿ä¼ÒÀÔ´Ï´Ù. Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ¸¶·ÃÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ: ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­: ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ¼¼°è¿¡¼­ Æó»öÀüÁõ°ú °üµ¿¸Æ Ç÷ÀüÁõÀÇ ÀÌȯÀ²ÀÌ Áõ°¡ Áß
      • ¿ì·ÎŰ³ªÁ¦ ±â¹Ý ÀǾàǰ¿¡ ´ëÇÑ Á¤ºÎÀÇ ½ÂÀÎ
    • ¾ïÁ¦¿äÀÎ
      • ÀǾàǰ °³¹ßÀÇ °íºñ¿ë°ú ´ëüǰÀÇ ÀÌ¿ë °¡´É¼º
    • ±âȸ
      • ¿ì·ÎŰ³ªÁ¦ÀÇ Àû¿ë¼ºÀ» Çâ»ó½Ã۱â À§ÇÑ Áö¼ÓÀûÀÎ ¿¬±¸ °³¹ß
      • ¿ì·ÎŰ³ªÁ¦ ±â¹Ý Ä¡·áÀÇ È¿´ÉÀ» ³ôÀ̱â À§ÇÑ °í±Þ ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ Ã¤¿ë
    • °úÁ¦
      • ¿ì·ÎŰ³ªÁ¦°è ¾àÁ¦¿¡ ¼ö¹ÝÇÏ´Â ºÎÀÛ¿ë
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
    • À¯Çü : ¿ì·ÎŰ³ªÁ¦ ÆÄ¿ì´õ´Â º¸Á¸ ±â°£ÀÌ ±æ±â ¶§¹®¿¡ ¸Å¿ì ¼±È£µË´Ï´Ù
    • ÀÀ¿ë : º´¿ø¿¡¼­ Áß¿äÇÑ Ä¡·áÁ¦·Î¼­ ¿ì·ÎŰ³ªÁ¦ÀÇ ÀÀ¿ë È®´ë
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »ç±³
    • ±â¼úÀû
    • ¹ý·ü»ó
    • ȯ°æ

Á¦6Àå ¿ì·ÎŰ³ªÁ¦ ½ÃÀå : À¯Çüº°

  • ¿ì·ÎŰ³ªÁ¦ ÆÄ¿ì´õ
  • ¿ì·ÎŰ³ªÁ¦ ¼Ö·ç¼Ç

Á¦7Àå ¿ì·ÎŰ³ªÁ¦ ½ÃÀå : ¿ë·® °­µµº°

  • 250000 À¯´Ö
  • 5000 À¯´Ö

Á¦8Àå ¿ì·ÎŰ³ªÁ¦ ½ÃÀå : ÀûÀÀÁõº°

  • Ä«Å×ÅÍ Å¬¸®¾î·±½º
  • °ü»óµ¿¸ÆÇ÷ÀüÁõ
  • ½ÉºÎÁ¤¸ÆÇ÷ÀüÁõ
  • Æó»öÀüÁõ

Á¦9Àå ¿ì·ÎŰ³ªÁ¦ ½ÃÀå : ¿ëµµº°

  • º´¿ø
  • ¿¬±¸±â°ü
  • Àü¹® Ŭ¸®´Ð

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ ¿ì·ÎŰ³ªÁ¦ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¿ì·ÎŰ³ªÁ¦ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¿ì·ÎŰ³ªÁ¦ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
    • Àü·«Àû Á¦ÈÞ¿¡ ÀÇÇØ KinlyticÀÌ ºÎȰ : Ç÷Àü ¿ëÇØ ¿ä¹ýÀÇ È¹±âÀûÀÎ »ç°Ç
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸ñ·Ï

  • Abbott Laboratories
  • BBT Biotech GmbH
  • Cerbios-Pharma SA
  • Echelon Biosciences
  • Ilex Life Sciences LLC
  • JCR Pharmaceuticals Co., Ltd.
  • Jiangsu Aidea Pharmaceutical Co., Ltd
  • Jiangxi Haoran Bio-pharma Co., Ltd.
  • Kraeber & Co GmbH
  • Merck KGaA
  • Microbix Biosystems Inc.
  • Midas Pharma GmbH
  • Pfizer Inc.
  • Syner-Med Pharmaceuticals
  • Taj Pharmaceuticals Ltd.
  • Thermo Fisher Scientific Inc.
  • VWR International, LLC
  • Wanhua Biochem Products Co. Ltd.
  • Zydus Lifesciences Limited
JHS 25.01.02

The Urokinase Market was valued at USD 1.76 billion in 2023, expected to reach USD 1.85 billion in 2024, and is projected to grow at a CAGR of 5.30%, to USD 2.52 billion by 2030.

Urokinase, an enzyme used to dissolve blood clots, plays a pivotal role in thrombolytic therapy, particularly in conditions such as myocardial infarction and pulmonary embolism. The market for urokinase is defined by its application in emergency medicine, providing life-saving interventions where rapid clot dissolution is crucial. Necessity arises from its effectiveness in treating acute thrombotic conditions, with a growing demand influenced by the rising incidence of cardiovascular diseases globally. The scope of urokinase extends to hospitals, specialty clinics, and research laboratories where it's used both therapeutically and experimentally. The market is influenced by factors such as an aging population, increasing healthcare expenditure, and advancements in biotechnology driving product enhancement. However, significant growth barriers include high therapy costs, stringent regulatory requirements, and competition from alternative therapies like tissue plasminogen activator (tPA).

KEY MARKET STATISTICS
Base Year [2023] USD 1.76 billion
Estimated Year [2024] USD 1.85 billion
Forecast Year [2030] USD 2.52 billion
CAGR (%) 5.30%

Current opportunities lie in expanding urokinase's application into novel therapeutic areas, increased use in developing regions due to heightened awareness and healthcare infrastructure improvements, and potential development in bio-manufacturing to reduce costs. To capitalize on these opportunities, companies should focus on strategic partnerships and R&D investments to diversify urokinase applications while ensuring compliance with regulatory standards. Risks involve possible side effects, the emergence of biosimilars, and fluctuations in raw material availability, posing challenges to market penetration.

Innovation could focus on enhancing the specificity and efficacy of urokinase formulations, personalized medicine approaches to tailored thrombolytic therapy, and improved delivery mechanisms. Additionally, investments in large-scale clinical trials could provide insights into broader applications of urokinase, contributing valuable data that may favorably influence regulators and payers. The urokinase market is dynamic, characterized by a competitive landscape where continuous innovation and strategic leanings towards cost-effective production and wide-scale application are key for sustainable growth and resilience against market challenges.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Urokinase Market

The Urokinase Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of pulmonary embolism and coronary artery thrombosis worldwide=
    • Supportive government approvals for urokinase-based medications
  • Market Restraints
    • High costs of drug development and availability of alternatives
  • Market Opportunities
    • Ongoing research and development to improve the applicability of urokinase
    • Adoption of advanced drug delivery systems to enhance the effectiveness of urokinase-based treatments
  • Market Challenges
    • Side effects associated with urokinase-based drugs

Porter's Five Forces: A Strategic Tool for Navigating the Urokinase Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Urokinase Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Urokinase Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Urokinase Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Urokinase Market

A detailed market share analysis in the Urokinase Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Urokinase Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Urokinase Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Urokinase Market

A strategic analysis of the Urokinase Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Urokinase Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, BBT Biotech GmbH, Cerbios-Pharma SA, Echelon Biosciences, Ilex Life Sciences LLC, JCR Pharmaceuticals Co., Ltd., Jiangsu Aidea Pharmaceutical Co., Ltd, Jiangxi Haoran Bio-pharma Co., Ltd., Kraeber & Co GmbH, Merck KGaA, Microbix Biosystems Inc., Midas Pharma GmbH, Pfizer Inc., Syner-Med Pharmaceuticals, Taj Pharmaceuticals Ltd., Thermo Fisher Scientific Inc., VWR International, LLC, Wanhua Biochem Products Co. Ltd., and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Urokinase Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Urokinase Powder and Urokinase Solution.
  • Based on Dose Strength, market is studied across 250000 Unit and 5000 Unit.
  • Based on Indication, market is studied across Catheter Clearance, Coronary Artery Thrombosis, Deep Vein Thrombosis, and Pulmonary Embolism.
  • Based on Application, market is studied across Hospital, Research Institutions, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of pulmonary embolism and coronary artery thrombosis worldwide=
      • 5.1.1.2. Supportive government approvals for urokinase-based medications
    • 5.1.2. Restraints
      • 5.1.2.1. High costs of drug development and availability of alternatives
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development to improve the applicability of urokinase
      • 5.1.3.2. Adoption of advanced drug delivery systems to enhance the effectiveness of urokinase-based treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with urokinase-based drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Significant preference towards urokinase powder due to superior shelf life
    • 5.2.2. Application: Expanding application of urokinase in hospitals as a pivotal therapeutic agent
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Urokinase Market, by Type

  • 6.1. Introduction
  • 6.2. Urokinase Powder
  • 6.3. Urokinase Solution

7. Urokinase Market, by Dose Strength

  • 7.1. Introduction
  • 7.2. 250000 Unit
  • 7.3. 5000 Unit

8. Urokinase Market, by Indication

  • 8.1. Introduction
  • 8.2. Catheter Clearance
  • 8.3. Coronary Artery Thrombosis
  • 8.4. Deep Vein Thrombosis
  • 8.5. Pulmonary Embolism

9. Urokinase Market, by Application

  • 9.1. Introduction
  • 9.2. Hospital
  • 9.3. Research Institutions
  • 9.4. Specialty Clinics

10. Americas Urokinase Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Urokinase Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Urokinase Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Strategic Alliance Revives Kinlytic: A Milestone in Thrombolytic Therapy
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. BBT Biotech GmbH
  • 3. Cerbios-Pharma SA
  • 4. Echelon Biosciences
  • 5. Ilex Life Sciences LLC
  • 6. JCR Pharmaceuticals Co., Ltd.
  • 7. Jiangsu Aidea Pharmaceutical Co., Ltd
  • 8. Jiangxi Haoran Bio-pharma Co., Ltd.
  • 9. Kraeber & Co GmbH
  • 10. Merck KGaA
  • 11. Microbix Biosystems Inc.
  • 12. Midas Pharma GmbH
  • 13. Pfizer Inc.
  • 14. Syner-Med Pharmaceuticals
  • 15. Taj Pharmaceuticals Ltd.
  • 16. Thermo Fisher Scientific Inc.
  • 17. VWR International, LLC
  • 18. Wanhua Biochem Products Co. Ltd.
  • 19. Zydus Lifesciences Limited
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦